Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

InDex raises $20m to bring ulcerative colitis drug to market

This article was originally published in Scrip

Executive Summary

Swedish drug developer InDex Pharmaceuticals has raised $20m in an oversubscribed financing round, which will help the company move its lead compound Kappaproct towards the market. Kappaproct is currently in Phase III development for ulcerative colitis, with results from the COLLECT study expected in the summer.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC024558

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel